BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18594829)

  • 1. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.
    Cao W; Shiverick KT; Namiki K; Sakai Y; Porvasnik S; Urbanek C; Rosser CJ
    World J Urol; 2008 Oct; 26(5):509-16. PubMed ID: 18594829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation.
    Cao W; Yacoub S; Shiverick KT; Namiki K; Sakai Y; Porvasnik S; Urbanek C; Rosser CJ
    Prostate; 2008 Aug; 68(11):1223-31. PubMed ID: 18465755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
    Canfield SE; Zhu K; Williams SA; McConkey DJ
    Mol Cancer Ther; 2006 Aug; 5(8):2043-50. PubMed ID: 16928825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
    Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
    Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
    Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
    Hu W; Zheng RR; Cui HX; Yue D; Wang Y; Jiang YH
    Asian J Androl; 2012 Sep; 14(5):695-702. PubMed ID: 22902909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T; Tanaka Y; Tamaki H; Harada M
    Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
    Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
    Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
    Nawrocki ST; Sweeney-Gotsch B; Takamori R; McConkey DJ
    Mol Cancer Ther; 2004 Jan; 3(1):59-70. PubMed ID: 14749476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.
    Anai S; Goodison S; Shiverick K; Hirao Y; Brown BD; Rosser CJ
    Mol Cancer Ther; 2007 Jan; 6(1):101-11. PubMed ID: 17237270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C; Li R; Grandis JR; Johnson DE
    Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of cell killing by ABT-737 synergized with docetaxel in human prostate cancer PC-3 cells].
    Hao JW; Mao XP; Ding DG; Du GH; Liu ZH
    Zhonghua Wai Ke Za Zhi; 2012 Feb; 50(2):161-5. PubMed ID: 22490358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.
    Goktas S; Baran Y; Ural AU; Yazici S; Aydur E; Basal S; Avcu F; Pekel A; Dirican B; Beyzadeoglu M
    Urology; 2010 Apr; 75(4):793-8. PubMed ID: 19800672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
    Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
    Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
    Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.
    Xu L; Yang D; Wang S; Tang W; Liu M; Davis M; Chen J; Rae JM; Lawrence T; Lippman ME
    Mol Cancer Ther; 2005 Feb; 4(2):197-205. PubMed ID: 15713891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
    Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
    Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
    Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.